Cutaneous manifestations of diabetes

Diagnosis of Aging Skin Diseases

Volumn , Issue , 2008, Pages 253-263

  Chakrabarty, Arun ^a   Norman, Robert A ^b   Phillips, Tania J ^c  

^a Solano Clinical Research   (United States)

^b Dermatology Health Care   (United States)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84857404076     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-84628-678-0_20     Document Type: Chapter

References (59)

1. Nathan M. Long-term complications of diabetes mellitus. N. Engl. J. Med. 1993; 305: 1676-85.
2. Jelinek JE. Cutaneous manifestations of diabetes mellitus. Int. J. Dermatol. 1994; 33: 605-17.
3. Norman A. Dermal Manifestations of Diabetes. New York: Geriatric Dermatology Text, 2001, pp. 143-54.
4. Perez I, Kohn R. Cutaneous manifestations of diabetes. J. Am. Acad. Dermatol. 1994; 30: 519-31.
5. Meurer M, Szeimies RM. Diabetes mellitus and skin diseases. Curr. Probl. 1991; 20: 11-23.
6. Braverman IM. Skin Signs of Systemic Disease. Philadelphia, PA: WB Saunders Text, 1981, 654-64.
7. Huntley AC. Cutaneous manifestations of diabetes mellitus. Dermatol. Clin. 1989; 7: 531-46.
8. Huntley AC. The cutaneous manifestations of diabetes mellitus. J. Am. Acad. Dermatol. 1982; 7: 427-55.
9. Muller SA. Dermatologic disorders associated with diabetes mellitus. Mayo Clin. Proc. 1966; 41: 689-703.
10. Sibbald RG, Schachter RK. The skin and diabetes mellitus. Int. J. Dermatol. 1984; 23: 567-84.
11. Boulton AJM, Cutfield RG, Abouganem D, et al. Necrobiosis lipoidica diabeticorum: A clinicopathologic study. J. Am. Acad. Dermatol. 1988; 18: 530-7.
12. Stratham B, Finlay AY, Marks R. A randomized double-blind comparison of aspirin and dipyridamole combination versus a placebo in the treatment of necrobiosis lipoidica. Acta Derm. Venereol. (Stockh) 1981; 61: 270-1.
13. Schwartz A. Acanthosis nigricans. J. Am. Acad. Dermatol. 1994; 31: 1-19.
14. Kahn CR, Flier JS, Bar RS, et al. The syndromes of insulin resistance and acanthosis nigricans: insulin-receptor disorders in man. N. Engl. J. Med. 1976; 294: 739-45.
15. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-607.
16. Electronic Textbook of Dermatology. http://www. telemedicine. org/stamford.
17. Tsushima T, Omori Y, Murakami H, et al. Demonstration of heterogeneity of autoantibodies to insulin receptors in type B insulin resistance by isoelectric focusing. Diabetes 1989; 38: 1090-6.
18. Moller DE, Cohen O, Yamaguchi Y, et al. Prevalence of mutations in the insulin receptor gene in subjects with features of the type A syndrome of insulin resistance. Diabetes 1994; 43: 247-55.
19. Moller DE, Flier JS. Insulin resistance-mechanisms, syndromes, and implications. N. Engl. J. Med. 1991; 325: 938-48.
20. Rendon MI, Cruz PD Jr, Sonthheimer RD, et al. Acanthosis nigricans: A cutaneous marker of tissue resistance to insulin. J. Am. Acad. Dermatol. 1989; 21: 461-9.
21. Taylor SI. Lilly lecture: molecular mechanisms of insulin resistance. Lessons from patients with mutations in the insulin-receptor gene. Diabetes 1992; 41: 1473-90.
22. Cama A, Sierra MDDL, Ottini L, et al. A mutation in the tyrosine kinase domain of the insulin receptor associated with insulin resistance in an obese woman. J. Clin. Endocrinol. Metabol. 1991; 73: 894-901.
23. Cruz PD Jr, Hud JA Jr. Excess insulin binding to insulin like growth factor receptors: proposed mechanism for acanthosis nigricans. J. Invest. Dermatol. 1992; 98(Suppl): 82S-5S.
24. Shemer A, Bergman R, Linn S, et al. Diabetic dermopathy and internal complications in diabetes mellitus. Int. J. Dermatol. 1998; 37(2): 113-5.
25. Bauer M, Levan NE. Diabetic dermangiopathy: A spectrum including pretibial pigmented patches and necrobiosis lipoidica diabeticorum. Br. J. Dermatol. 1970; 83: 528-35.
26. Binkley GW, Giraldo B, Stoughton RB. Diabetic dermopathy: A clinical study. Cutis 1967; 3: 955-8.
27. Huntley AC, Walter RM. Quantitative evaluation of skin thickness in diabetes mellitus: relationship to disease parameters. J. Med. 1990; 21: 257-64.
28. Brik R, Berant M, Verdi P. The scleroderma-like syndrome of insulin-dependent diabetes mellitus. Diabetes Metab. Rev. 1991; 7: 121-8.
29. Hanna W, Friesen D, Bombardier C, et al. Pathologic features of diabetic thick skin. J. Am. Acad. Dermatol. 1987; 16: 546-53.
30. Fleischmajer R, Damiano V, Nedwich A. Alteration of subcutaneous tissue in systemic scleroderma. Arch. Dermatol. 1972; 105: 59-66.
31. Hayes RL, Rodnan GP. The ultrastructure of skin in progressive systemic sclerosis (scleroderma). I. Dermal collage fibers. Am. J. Pathol. 1971; 63: 433-42.
32. Fleischmajer R, Gay S, Perlish JS, et al. Immunoelectron microscopy of type III collagen in normal and scleroderma skin. J. Invest. Dermatol. 1980; 75: 189-91.
33. Fleischmajer R, Perlish JS. Glycosaminoglycans in scleroderma and scleredema. J. Invest. Dermatol. 1972; 58: 129-32.
34. Eaton PR. The collagen hydration hypothesis: A new paradigm for the secondary complications of diabetes mellitus. J. Chronic Dis. 1986; 39: 753-66.
35. Buckingham BA, Uitto J, Sandborg C, et al. Scleredema-like changes in insulin dependent diabetes mellitus: clinical and biochemical studies. Diabetes Care 1984; 7: 163-9.
36. Lieberman LS, Rosenblum AL, Riley WJ, et al. Reduced skin thickness with pump administration of insulin. N. Engl. J. Med. 1980; 303: 940-1.
37. Bernstein JE, Medenica M, Soltani K, et al. Bullous eruption of diabetes mellitus. Arch. Dermatol. 1979; 115: 324-5.
38. Toonstra J. Bullous diabeticorum. J. Am. Acad. Dermatol. 1985; 13: 799-805.
39. Sibald GR, et al. Skin and diabetes. Endocrinol. Metab. Clin. North Am. 1996; 25: 463-72.
40. Miller F III. Management of diabetic foot ulcers. J. Cutan. Med. Surg. 1998; 3(Suppl. 1): 13-17.
41. Bleich HL, Boro ES. Diabetic polyneuropathy: the importance of insulin deficiency, hyperglycemia and alterations in myoinositol metabolism in its pathogenesis. N. Engl. J. Med. 1976; 295: 1416-20.
42. Grunfeld C. Diabetic foot ulcers: etiology, treatment, and prevention. Adv. Intern. Med. 1991; 37: 103-32.
43. Caputo M, Cavanagh P, Ulbrecht J, et al. Assessment and management of foot disease in patients with diabetes. N. Engl. J. Med. 1994; 331: 854-60.
44. Cavanagh P, Buse J, Frykberg R, et al. Consensus development conference on diabetic foot wound care. Diabetes Care 1999; 22: 1354-60.
45. Veves A, Falanga V, Armstrong DG, et al. Graftskin, a human skin equivalent, is effective in the management of noninfected neuropathic diabetic foot ulcers: A prospective randomized multicenter clinical trial. Diabetes Care 2001; 24(2): 290-5.
46. Meurer M, Szeimies RM. Diabetes mellitus and skin diseases. Curr Probl 1991; 20: 11-23.
47. Knight L, Fletcher J. Growth of Candida albicans in saliva: stimulation by glucose associated with antibiotics, steroids, and diabetes mellitus. J. Infect. Dis. 1971; 123: 371-7.
48. Tierney MR, Baker AS. Infections of the head and neck in diabetes mellitus. Infect. Dis. Clin. North Am. 1995; 9(1): 195-216.
49. Petrozzi JW, Warthan TL. Malignant external otitis. Arch. Dermatol. 1974; 110: 258-60.
50. Rapini RP, Hebert AA, Drucker CR. Acquired perforating dermatosis: evidence for combined transepidermal elimination of both collagen and elastic fibers. Arch. Dermatol. 1989; 125: 1074-8.
51. Zelger B, Hintner H, Aubock J, et al. Acquired perforating dermatosis: transepidermal elimination of DNA material and possible role of leukocytes in pathogenesis. Arch. Dermatol. 1991; 127: 695-700.
52. Berger RS. Reactive perforating collagenosis of renal failure: diabetes responsive to topical retinoic acid. Cutis 1989; 43: 540-2.
53. Chan LY, Tang WY, Lo KK. Treatment of pruritus of reactive perforating collagenosis using transcutaneous electrical nerve stimulation. Eur. J. Dermatol. 2000; 10(1): 59-61.
54. Kruger K, Tebbe B, Krengel S, et al. Acquired reactive perforating dermatosis. Successful treatment with allopurinol in 2 cases. Hautarzt 1999; 50(2): 115-20.
55. Cruz PO, East C, Berstresser PR. Dermal, subcutaneous, and tendon exanthomas: diagnostic markers for specific lipoprotein disorders. J. Am. Acad. Dermatol. 1988; 19: 95-111.
56. Cohen-Sabban E, Cabo H,Woscoff A. Dermatoses most frequently related to diabetes. J. Clin. Dermatol. 1999; 2: 15-22.
57. Burnham TK, Fosnaugh RP. Porphyria, diabetes, and their relationship. Arch. Dermatol. 1961; 83: 55-60.
58. Epstein JH, Tuffanelli DL, Epstein WL. Cutaneous changes in the porphyrias. Arch. Dermatol. 1973; 107: 689-98.
59. Fitzpatrick TB, RA Johnson, Wolff K. Color Atlas and Synopsis of Clinical Dermatology, 4th ed. New York: McGraw-Hill, 2001, 120-2.